Vericiguat

• REPO-HYPER II Recruiting
  2024-520231-33-00 Phase II 1 country Karolinska University Hospital
• Vericiguat in Vasospastic Angina (ViVA) Recruiting
  2022-502998-42-00 Phase II 1 country Amsterdam UMC
• A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua… Recruiting
  2022-501238-52-00 Phase II/III 14 countries Merck Sharp & Dohme LLC
• ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with… Ended
  2024-514111-10-00 Phase IV 1 country Rigshospitalet
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 Phase III 13 countries Merck Sharp & Dohme LLC
• A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended
  2023-507682-25-00 Phase II 5 countries Bayer AG
• A study to investigate improvement in physical function in SF-36 with Vericiguat compared with Placebo in participants with post-COVID-19 sy… Ended
  2024-517713-33-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 Phase III 12 countries Merck Sharp & Dohme LLC

Showing 1–8 of 8 trials